TY - JOUR
T1 - Rash from newer cancer agents
T2 - Why do we still not have effective therapy for palliation and/or prevention?
AU - Butts, Matthew
AU - Jatoi, Aminah
PY - 2010/7
Y1 - 2010/7
N2 - In their paper, "Dermatologic Toxicities of Targeted Anticancer Therapies," Balagula and others provide a thorough discussion of cutaneous adverse events from newer, targeted anticancer agents. These agents include epidermal growth factor receptor (EGFR) inhibitors, as well as several other multikinase inhibitors. The authors describe the spectrum of skin, hair, and nail changes that arise from several such agents and comprehensively expound upon the psychosocial and physical discomfort of such toxicities.
AB - In their paper, "Dermatologic Toxicities of Targeted Anticancer Therapies," Balagula and others provide a thorough discussion of cutaneous adverse events from newer, targeted anticancer agents. These agents include epidermal growth factor receptor (EGFR) inhibitors, as well as several other multikinase inhibitors. The authors describe the spectrum of skin, hair, and nail changes that arise from several such agents and comprehensively expound upon the psychosocial and physical discomfort of such toxicities.
UR - http://www.scopus.com/inward/record.url?scp=77956112522&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956112522&partnerID=8YFLogxK
M3 - Article
C2 - 20822033
AN - SCOPUS:77956112522
SN - 1544-6794
VL - 8
SP - 162
EP - 163
JO - Journal of Supportive Oncology
JF - Journal of Supportive Oncology
IS - 4
ER -